Home - Products - Others - Other Targets - 2,2-Dimethyl-5-(2,5-xylyloxy)valeramide

2,2-Dimethyl-5-(2,5-xylyloxy)valeramide

CAS No. 114413-97-7

2,2-Dimethyl-5-(2,5-xylyloxy)valeramide( 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide )

Catalog No. M28379 CAS No. 114413-97-7

2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 35 In Stock
5MG 29 In Stock
10MG 43 In Stock
25MG 73 In Stock
50MG 107 In Stock
100MG 160 In Stock
200MG 241 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    2,2-Dimethyl-5-(2,5-xylyloxy)valeramide
  • Note
    Research use only, not for human use.
  • Brief Description
    2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.
  • Description
    2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Na+/H+-exchanger (NHE)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    114413-97-7
  • Formula Weight
    249.354
  • Molecular Formula
    C15H23NO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cc1ccc(C)c(OCCCC(C)(C)C(N)=O)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Timothy A. Ayers, et al. Process for preparing 2-chloro-3n-(2-benzimidazolyl)-4-methyl-3-thienylamine useful as a sodium/proton exchanger type 3 inhibitor. WO2011019784A1
molnova catalog
related products
  • Ethyl chrysanthemuma...

    Ethyl chrysanthemumate is an allelochemical compound used as an attractant.

  • Crenulatin

    Crenulatin has dual- direction effects on apoptosis of cerebral microvascular endothelial cells, inhibitive effect in 25 mg/L and stimulative effect in 100 mg/L group, respectively; the mechanism is related to the alterations of Fas/Bcl-2 expression and caspase-3 activity.

  • Somatostatin-14 (3-1...

    Somatostatin-14 (3-10)